October 8, 2026
FDA approves Pfizer’s Tukysa regimen for metastatic breast cancer
The US Food and Drug Administration (FDA) has approved Pfizer’s Tukysa (tucatinib) along with pertuzumab and trastuzumab as a maintenance therapy for breast cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.







